Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma by Pfitzenmaier Jesco et al.
RESEARCH ARTICLE Open Access
Enhancer of zeste homolog 2 (EZH2) expression
is an independent prognostic factor in renal cell
carcinoma
Nina Wagener
1,2, Stephan Macher-Goeppinger
3, Maria Pritsch
4, Johannes Hüsing
5, Karin Hoppe-Seyler
1,
Peter Schirmacher
3, Jesco Pfitzenmaier
6, Axel Haferkamp
7, Felix Hoppe-Seyler
1*, Markus Hohenfellner
2*
Abstract
Background: The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression
has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression
and prognosis in patients with renal cell carcinoma (RCC).
Methods: EZH2 protein expression in RCC specimens was analyzed by immunohistochemistry using a tissue
microarray (TMA) containing RCC tumor tissue and corresponding normal tissue samples of 520 patients. For
immunohistochemical assessment of EZH2 expression, nuclear staining quantity was evaluated using a
semiquantitative score. The effect of EZH2 expression on cancer specific survival (CSS) was assessed by univariate
and multivariate Cox regression analyses.
Results: During follow-up, 147 patients (28%) had died of their disease, median follow-up of patients still alive was
6.0 years (range 0-16.1 years). EZH2 nuclear staining was present in tumor cores of 411 (79%) patients. A
multivariate Cox regression analysis revealed that high nuclear EZH2 expression was an independent predictor of
poor CSS (> 25-50% vs. 0%: HR 2.72, p = 0.025) in patients suffering from non-metastatic RCC. Apart from high
nuclear EZH2 expression, tumor stage and Fuhrman’s grading emerged as significant prognostic markers. In
metastatic disease, nuclear EZH2 expression and histopathological subtype were independent predictive
parameters of poor CSS (EZH2: 1-5%: HR 2.63, p = 0.043, >5-25%: HR 3.35, p = 0.013, >25%-50%: HR 4.92, p = 0.003,
all compared to 0%: HR 0.36, p = 0.025, respectively).
Conclusions: This study defines EZH2 as a powerful independent unfavourable prognostic marker of CSS in
patients with metastatic and non-metastatic RCC.
Background
Renal cell carcinoma (RCC) is estimated to account for
more than 57000 new cases and 13000 cancer-related
deaths in the United States in 2009, making it the sec-
ond most lethal of all urological cancers [1]. Defects in
von Hippel-Lindau (VHL) tumor suppressor gene func-
tion appears to be one key event in clear cell RCC, in
both hereditary and sporadic cases [2]. However, the
variable clinical picture of the resulting neoplasms is
likely to be strongly determined by the complex inter-
play of additional cellular alterations, among which the
role of epigenetic modulation of gene expression is
becoming more and more acknowledged [2].
The enhancer of zeste homolog 2 (EZH2) gene encodes
a polycomb group (PcG) protein which acts as a histone
methyltransferase [3,4] and also may control DNA
methylation [5]. There is accumulating experimental
evidence that EZH2 can contribute to the deregulation of
cellular growth as a bona fide oncogene. Overexpression
of EZH2 conferred cellular growth advantage in vitro
[6,7], promoted invasion [7], and exhibited oncogenic
properties in nude mice [8]. Vice versa, inhibition of
* Correspondence: hoppe-seyler@dkfz.de; Markus.Hohenfellner@med.uni-
heidelberg.de
1German Cancer Research Center, Molecular Therapy of Virus-Associated
Cancers (F065), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
2Department of Urology, University of Heidelberg, Im Neuenheimer Feld 110,
69120 Heidelberg, Germany
Full list of author information is available at the end of the article
Wagener et al. BMC Cancer 2010, 10:524
http://www.biomedcentral.com/1471-2407/10/524
© 2010 Wagener et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.EZH2 expression by antisense constructs or RNA inter-
ference (RNAi) resulted in growth inhibition of cancer
cells [9,10], and induced anoikis in circulating prostate
carcinoma precursor cells [11] or apoptotic cell death in
breast cancer cells [12]. We recently found that inhibition
of endogenous EZH2 expression in RCC cell lines by
RNAi was linked to reduced proliferation and increased
apoptosis in RCC [13] and cervical carcinoma cells [14].
Notably, EZH2 may serve as a novel marker with
potential for clinical oncology. EZH2 expression was
linked to an increased risk for breast cancer develop-
ment in females [15,16], suggesting that EZH2 detection
could have diagnostic value for this cancer form.
Furthermore, in both prostate [9,17] and breast cancer
[7,17], EZH2 expression was associated to more aggres-
sive tumor subgroups, indicating that EZH2 expression
may also serve as a novel prognostic marker.
In view of its growth-promoting activities in RCC cell
lines [13], we here investigated the potential of EZH2 to
serve as a prognostic marker for RCC. EZH2 protein
expression was analyzed in primary RCC specimens and
in corresponding non-tumorous tissue, using a tissue
microarray (TMA) encompassing tissue cores of 520
patients. In addition, we investigated the association of
EZH2 expression with cancer specific survival (CSS) in
univariate and multivariate Cox regression analyses. We
show that EZH2 is significantly overexpressed in pri-
mary RCC, when compared with histologically normal
renal tissue. Moreover, high nuclear EZH2 expression in
non-metastatic disease, and nuclear EZH2 expression in
metastatic disease are unfavourable independent predic-
tive parameters of CSS. The concordance probability of
the Cox regression models including EZH2 was higher
compared to models excluding EZH2, for both meta-
static and non-metastatic disease. We conclude that
EZH2 is a powerful and independent predictor of RCC-
related death, which can add to the development of a
modified risk stratification system.
Methods
Patients
Clinical data of patients (n = 768) with RCC who under-
went radical nephrectomy or nephron-sparing surgery at
the Department of Urology, University of Heidelberg,
between 1990 and 2005 and had no other malignant
tumor before or within one month after surgery were
entered into a prospective database. Tumor stage was
classified according to the tumor node metastasis sta-
ging system of 2002, tumors were graded on the basis
the Fuhrman four-tiered nuclear grading system. In
patients with metastases, the Motzer criteria (haemoglo-
bin, corrected calcium, and Karnofsky performance
scale) [18] were evaluated and patients categorized to
one of the following risk groups: low, intermediate or
high risk. Patients were prospectively evaluated every
3 months for the first 2 years after surgery, every
6 months for the next 3 years, and yearly thereafter
(chest x-ray or thoracic CT scan; abdominal sonography
or CT scan or MRI; serum chemistry). No adjuvant
therapy was administered after radical surgery. Patients
with metastases, a Karnofsky severity rating ≥ 80, and
with no medical contraindications received palliative
Interferon-alpha- and Interleukin-2-based immunother-
apy. No tyrosine kinase inhibitors have been given.
The work was covered by a votum of the ethical com-
mittee of the University of Heidelberg No. 206/2005.
Informed and/or written consent was obtained from
each patient.
Tissue micro arrays
Tissue samples of all 768 patients included in the pro-
spective clinical database were obtained from the Tissue
Bank of the National Center for Tumor Diseases (NCT)
Heidelberg and included in a TMA, containing 768
primary tumor and corresponding normal tissue samples,
as previously described [19]. Briefly, representative tissue
blocks were selected as donor blocks for the TMA. Sec-
tions were cut from each donor block and stained with
H&E. Then, a morphologically representative region was
chosen from each of the RCC and normal renal tissue
samples. Two cylindrical core tissue specimen per tumor
block (diameter, 0.6 mm) were punched from these
regions and arrayed into the recipient paraffin block
using a semiautomatic system (Beecher Instruments,
Silver Spring, Maryland, USA). In total, 16 tissue array
blocks were generated, eachc o n t a i n i n gu pt o2 0 0c o r e
tissue specimens, matching 50 patients per array.
Immunohistochemistry
The TMA slides were dewaxed and rehydrated using
xylene and a series of graded alcohols, followed by
heat induced antigen retrieval using a target retrieval
solution (S2031, DakoCytomation, Glostrup, Denmark)
in a pressure cooker for 10 min. Immunohistochemical
staining was performed on an automated staining sys-
tem (Techmate 500, DakoCytomation) with a mouse
monoclonal anti-EZH2 antibody (1:25, BD Transduc-
tion Laboratories, Franklin Lakes, NJ, USA) for 45 min
[15]. An avidin-biotin-complex peroxidase technique
using aminoethylcarbazole for visualisation and hema-
toxylin for counterstaining was applied. In accordance
with the manufacturers’ instructions, the following
solutions were used: ChemMate Detection Kit (K5003,
DakoCytomation), ChemMate Buffer Kit (K5006,
DakoCytomation), and, for reduction of non-specific
avidin/biotin-related staining, the Avidin/Biotin Block-
ing Kit (SP-2001, Vector Laboratories, Burlingame,
USA). Sections were thoroughly washed, glass covered,
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Hamburg, Germany), using a magnification of up to ×
400. Specificity controls of the anti-EZH2 antibody
included iliac lymph node metastases of prostate carci-
noma [17] showing typical staining pattern. Moreover,
reactive infiltrating lymphocytes, which express detect-
able amounts of EZH2 protein [20], served as addi-
tional internal positive controls. As a negative control
for the immunohistochemical staining procedure, the
primary antibody was omitted, with all other experi-
mental conditions kept constant. For immunohisto-
chemical assessment of EZH2 expression, frequency of
nuclear staining was evaluated using a semiquantitative
score: 0 = no expression; 1 = positivity in 1 to 5% =
low expression; 2 = positivity in >5 to 25% = inter-
mediate expression; 3 = positivity in >25 to 50% =
high expression; and 4 = positivity in more than 50% =
very high expression. The arrays were independently
scored by two researcher blinded for patient outcomes.
For the few instances of discrepant scoring, a consen-
sus score was determined.
Study design
The study has been conducted on the REporting recom-
mendations for tumour MARKer prognostic studies
(REMARK) of the NCI-EORTC Working Group on
Cancer Diagnostics [21]. A retrospective study design
was chosen, based on a prospective clinical database.
Data analysis commenced in June 2006. Median follow-
up of patients still alive was 6.0 years (range 0-16.1 years).
Patients’ CSS was calculated from the date of renal
surgery. The survival endpoint was the date of last fol-
low-up or death. Kaplan-Meier estimates were used to
describe survival rates including pointwise asymptotic
95%-confidence intervals using Greenwood’sf o r m u l a
for standard error. Patients with proven tumor inde-
pendent death were censored. Furthermore, assuming
independence of the occurrence of RCC and other pri-
mary tumors in the same patient, patient survival was
censored at the time of the occurrence of a second
malignoma.
The following clinical and pathological features were
studied for their prognostic relevance on long term sur-
vival of RCC patients: Age (≥65 years vs. <65 years), sex
(male vs. female), performance status (Karnofsky severity
rating <80 vs. ≥80), tumor stage (Stage II, III, IV vs. I),
Fuhrman’s grade (grade 2, 3/4 vs. 1), histopathological
subtype (clear cell RCC vs. other types), nuclear EZH2
expression (1-5%, >5-25%, >25-50%, >50% vs. 0%).
Statistical analysis methods
Association between important prognostic factors and
EZH2 levels was evaluated by Fisher’s exact test, in case
of large contingency tables the Monte Carlo Simulation
was used.
For the evaluation of prognostic factors the study
population was divided into subgroups with and without
metastatic disease.
No data driven combination of adjacent categories
related to EZH2 expression was carried out to retain the
confirmatory nature of the evaluation of EZH2.
Univariate and multivariate analyses of prognostic fac-
tors were carried out within the Cox proportional
hazards model using complete cases analysis.
For each prognostic factor the hazard ratio in the uni-
variate analysis and the adjusted hazard ratio in the multi-
variate analysis are given, including the 95% confidence
interval. A p-value < 0.05 was considered significant. For
further description of the predictive value of EZH2 the
concordance probability [22] of the Cox models including
EZH2 were calculated and compared to the models
excluding EZH2 but retaining all other variables.
The statistical analysis system SAS, Version 9.2 for
Windows (SAS Institute Inc., Cary, NC, USA), the R
package, Version 2.8.0 (R Foundation for Statistical
Computing, Vienna, Austria), and StatXact, Version
8.0.0 (Cytel Inc., Cambridge, CA, USA) were used for
the analyses. For the calculation of the concordance
probability, the CPE package offered by Mo, Goenen
and Heller was used with the R programming language.
Results
In order to identify prognostic markers for RCC in a
large cohort of patients, a TMA was constructed which
contained RCC tumor tissue and corresponding normal
renal tissue samples from 768 patients. Expression of
EZH2 was analyzed by immunohistochemistry using a
mouse monoclonal anti-EZH2 antibody [15]. Altogether,
520 cases (non-metastatic disease n = 433, metastatic
disease n = 87) were scored for expression of EZH2.
The remaining cases with insufficient tumor tissue or
fixation artefacts were excluded from further analyses.
Typical examples are depicted in Figure 1. Negative
controls showed no immunohistochemical staining
(Figure 1A). Non-tumorous kidney tissue was mainly
negative for EZH2 expression (Figure 1B), only spora-
dically proximal and distal tubular epithelial cells and
infiltrating lymphocytes, if present in the tissue sample,
stained positive for EZH2. In contrast, EZH2 protein
expression was readily detected in 411 (79%) of the
cancerous tissues, typically showing nuclear staining
(Figures 1C and 1D), without predominately staining
of the central or peripheral zone of tumor. Ten (2%)
cases exhibited >50% EZH2-positive nuclei (Figure 1C),
36 (7%) >25-50% EZH2-positive nuclei, 99 (19%) >5-
25% EZH2-positive nuclei (Figure 1D), and 266 (51%)
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Figure 1 EZH2 protein expression in renal cell carcinoma (RCC) and corresponding normal tissue. A Negative control: RCC tissue
specimen (clear cell carcinoma), the anti-EZH2 antibody was omitted. B Normal adult kidney tissue, adjacent to the RCC tumor tissue shown in
C. C Overview (left panel) and higher resolution (right panel) of the boxed area of an RCC sample (clear cell carcinoma), showing very high
(> 50%) nuclear EZH2 expression (arrows). D Overview (left panel) and higher resolution (right panel) of an RCC sample (clear cell carcinoma)
showing >5-25% nuclear EZH2 expression (arrows). E Overview (left panel) and higher resolution of an RCC sample (clear cell carcinoma)
exhibiting 0% nuclear EZH2 staining. Scale bars, 5 μm.
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(21%) did not exhibit EZH2 nuclear staining in the
tumorous tissue (Figure 1E).
Next, the survival of patients with RCC was calculated
from the time of renal surgery. Until June 2006, 147
patients (28%) had died of their disease. The CSS rate at
1 year and at 5 years after surgery for the whole cohort
of patients was 88.4% (95 CI 86.1%-90.7%) and 70.8%
(95 CI 67.3%-74.4%), respectively. Clinical and patholo-
gical features of patients are summarized in Table 1.
Patients with advanced tumor stages (3 and 4), with
cancer infiltrated lymph nodes, distant metastases and/
or a high Fuhrman’s grading (grade 3/4) were found to
have significantly more often a higher percentage of
EZH2 nuclear staining when compared to patients with
localized tumor disease or low Fuhrman’s grading (grade
1/2). Moreover, nuclear EZH2 expression and the Mot-
zer criteria were found to be independent parameters,
whereas a dependency was seen between different
histopathological subtypes and nuclear EZH2 expression
(Table 2).
As shown in Figures 2A and 2B, Kaplan Meier cancer
specific survival curves of the whole cohort of patients
and of the non-metastatic subgroup revealed a worse
prognosis in patients with more than 25% nuclear EZH2
staining. In patients with metastatic disease, nuclear
EZH2 expression above 5% and up to 50% was an inde-
pendent predictor of poor CSS (Figure 2C).
On univariate survival analyses, the risk of death from
non-metastasized RCC for patients with high EZH2
positive nuclei (> 25%) was enhanced above that for
RCC patients who had no (0%) nuclear EZH2 staining.
Apart from EZH2, the following clinical and histopatho-
logical features showed a statistically significant impact
on CSS in non-metastasized RCC patients in univariate
analyses: tumor stage, grading, Karnofsky performance
status, and histopathological subtype (Table 3). In
metastasized RCCs, the risk of death for patients with
EZH2 positive nuclei (> 5% up to 50%) was clearly
enhanced above that for RCC patients who had no (0%)
nuclear EZH2 staining in the tumor. In patients who
had very high (> 50%) nuclear EZH2 staining, only a
negative tendency but no statistically significant impact
on CSS was seen, possibly due to the small number of
cases investigated for this group. The same findings
were observed for multivariate analyses, as discussed
further below. No other of the investigated clinical or
histopathological features showed a statistically signifi-
cant impact on CSS in univariate analyses (Table 4).
Next, we investigated whether EZH2 may also indepen-
dently correlate with CSS in RCC. Multivariate Cox
regression analyses on RCC outcome included tumor
stage, Fuhrman’s grading, Karnofsky performance status,
age, sex, histopathological subtype, and EZH2 expression.
These analyses revealed that >25-50% nuclear EZH2
expression in the tumor significantly correlated with an
increased risk of cancer specific death in patients suffer-
ing from non-metastasized RCC (HR 2.72, p = 0.025)
(Table 3). Apart from EZH2, tumor stage and high Fuhr-
man’s grading (3/4 vs. 1) emerged as significant prognos-
tic indicators, whereas sex, Karnofsky performance
status, age, and histopathological subtype did not inde-
pendently predict the clinical outcome. For metastasized
RCC, 1-5%, >5-25%, and >25-50% nuclear EZH2 expres-
sion was linked to decreased CSS when compared with
tumors with undetectable EZH2 expression (HR 2.63,
p = 0.043, HR 3.35, p = 0.013, HR 4.92, p = 0.003). For
the group of very high (> 50%) EZH2 expression no sig-
nificant influence on survival could be shown in compari-
son to the group with non-expression of EZH2. Tumor
stage, grading, Karnofsky performance status, age, and
sex did not predict clinical outcome, whereas clear
cell histology showed a positive correlation with CSS
Table 1 Summary of clinical and pathological features
(study population n = 520)
Feature Number of cases % of cases
Sex
Male 320 61.5
Female 200 38.5
Age at surgery
<65 years 295 56.7
≥65 years 225 43.3
Karnofsky perfomance status scale
≥80% 476 91.5
<80% 44 8.5
Tumor extent (Robson)
Stage I 310 59.6
Stage II 37 7.1
Stage III 83 16.0
Stage IV 90 17.3
Regional lymph node metastasis
N0/pN0 481 92.5
pN+ 39 7.5
Distant metastasis
M0 433 83.3
M+ 87 16.7
Fuhrman grade
G1/G2 417 80.2
G3/G4 98 18.8
Unclassified 5 1.0
Histopathological subtype
Clear cell RCC 422 81.1
Papillary (chromophilic) RCC 55 10.6
Chromophobe RCC 23 4.4
Duct bellini 3 0.6
Unclassified RCC 17 3.3
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with metastatic RCC (n = 51), we included EZH2 expres-
sion and the Motzer criteria as the only two factors in a
multivariate cox proportional hazards model, which
reviewed EZH2 as a borderline significant factor, despite
the small number of patients in the analyses (data not
shown).
Finally, for further evaluation of the predictive value of
EZH2 expression, the concordance probability of the
Cox regression models including or excluding EZH2
was calculated. In RCC patients without metastases, the
concordance probability of the Cox regression models
including the EZH2 status was 73.4%, compared to
71.8% in models excluding the EZH2 status but retain-
ing all other variables. In patients with RCC metastatic
disease, the concordance probability including EZH2
e x p r e s s i o nw a s6 8 . 4 % ,c o m p a r e dt o6 3 . 0 %i nm o d e l s
excluding EZH2 expression.
Discussion
The present study defines EZH2 as a powerful and inde-
pendent negative prognostic marker of CSS in patients
Table 2 Correlation of nuclear EZH2 expression with clinicopathological characteristics
Nuclear EZH2 expression
0% 1-5% >5-25% >25-50% >50%
n%n%n% n %n% p
Tumor extent (Robson) 0.0071
Stage I 65 60 167 63 61 62 14 39 3 30
Stage II 9 8 24 9 2 2 2 6 0 0
Stage III 20 18 38 14 15 15 8 22 2 20
Stage IV 15 14 37 14 21 21 12 33 5 50
Sex 0.984
Male 67 61 161 61 63 64 23 64 6 60
Female 42 39 105 39 36 36 13 36 4 40
Age at surgery 0.746
< 65 years 58 53 148 56 61 62 22 61 6 60
≥ 65 years 51 47 118 44 38 38 14 39 4 40
Karnofsky performance status scale 0.404
≥ 80% 100 92 241 91 92 93 35 97 8 80
< 80% 9 8 25 9 7 7 1 3 2 20
Tumor stage 0.019
pT1/2 72 66 177 67 70 71 17 47 3 30
pT3/4 37 34 89 33 29 29 19 53 7 70
Regional lymph node metastasis 0.003
N0/pN0 103 95 250 94 93 94 28 78 7 70
pN+ 6 5 16 6 6 6 8 22 3 30
Distant metastasis 0.005
M0 94 86 231 87 78 79 24 67 6 60
M+ 15 14 35 13 21 21 12 33 4 40
Fuhrman grade <0.0001
G1/G2 91 83 224 85 78 80 20 56 4 40
G3/G4 18 17 39 15 19 20 16 44 6 60
Histopathological subtype <0.001**
Clear cell RCC 88 81 226 85 71 72 31 86 6 60
Papillary (chromophilic) RCC 7 6 27 10 17 17 3 8 1 10
Chromophobe RCC 11 10 8 3 4 4 0 0 0 0
Duct Bellini 000000 2 61 1 0
Unclassified RCC 335277 0 02 2 0
Motzer criteria (metastatic RCC, n = 51) 0.731*
Favorable 1 11 1 6 0 0 2 20 0 0
Intermediate 6 67 11 61 6 55 5 50 3 100
Poor 2 22 6 33 5 45 3 30 0 0
Fisher’s exact test* using Monte Carlo Simulation**.
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assessment of EZH2 expression may allow improved
patient selection for systemic therapies. Moreover, inte-
gration of the EZH2 status into current prognostic mod-
els could result in more accurate survival prediction and
may also be useful for individualizing follow-up and
selecting patients for clinical trials.
RCC is commonly characterized by a poor response
towards current treatment options. Even after complete
resection of the primary tumor, relapse occurs in
Figure 2 Kaplan Meier survival curves of cancer specific survival (CSS). A CSS rates of RCC patients with non-metastatic and metastatic
disease. B CSS rates in non-metastasized RCC. C CSS rates in metastatic RCC.
Table 3 Analysis of cancer specific survival (CSS) in RCC, patients without metastases
Univariate Analysis Multivariate Analysis
Variable HR 95% CI p HR 95% CI p
Stage II vs. I 4.32 2.13-8.73 <0.0001 3.11 1.48-6.54 0.003
Stage III vs. I 8.94 5.35-14.93 <0.0001 4.84 2.66-8.80 <0.0001
Grading 2 vs. 1 1.42 0.73-2.75 0.302 1.11 0.55-2.23 0.768
Grading 3/4 vs. 1 8.91 4.51-17.59 <0.0001 2.74 1.26-5.95 0.011
Karnofsky < 80 vs. ≥ 80 3.02 1.66-5.48 0.0003 1.82 0.95-3.51 0.072
Age ≥ 65 years vs. < 65 years 1.50 0.95-2.35 0.081 1.01 0.62-1.65 0.965
Sex (Male vs. Female) 1.16 0.73-1.84 0.527 1.37 0.83-2.24 0.216
Clear cell RCC vs. non clear cell RCC 5.43 1.71-17.24 0.004 2.82 0.87-9.22 0.086
Nuclear EZH2 1-5% vs. 0% 1.16 0.64-2.10 0.615 1.21 0.66-2.21 0.546
Nuclear EZH2 >5-25% vs. 0% 0.57 0.23-1.39 0.215 0.60 0.22-1.59 0.301
Nuclear EZH2 >25-50% vs. 0% 3.44 1.54-7.67 0.003 2.72 1.14-6.50 0.025
Nuclear EZH2 >50% vs. 0% 5.11 1.47-17.76 0.010 2.20 0.28-17.42 0.456
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in patients with metastases, the median survival is only
about 13 months, with a 5-year survival of less than
10% [23,24]. Cytokine therapy and novel targeted thera-
pies, i.e. tyrosine kinase inhibitors, have been of limited
benefit [23,25-29]. Progression and treatment response
of the disease are still not sufficiently predictable. Suita-
ble molecular markers could help to refine individual
risk stratification and treatment plans [30]. However, for
RCC, as for other cancers in general, only few markers
have been validated for clinical practice. This may be
partly due to the fact that many studies have been small
and poorly designed, used inappropriate statistical analy-
sis, and employed different assay methods and outcome
measures [31].
The present study, defining EZH2 as a novel prognos-
tic marker in RCC, has been conducted according to the
REMARK criteria [21]. These include a large sample
size, a long prospective follow-up of patients, and a
description of the predictive value of the marker. Possi-
ble limitations of our study include the lack of external
validation using a second cohort of patients with RCC.
For analyzing RCC patients without metastases, our Cox
regression model-which included tumor stage, grading,
Karnofsky performance index, age, sex, histopathological
subtype, and EZH2 expression-revealed a concordance
probability of 73.4% compared to 71.8% excluding EZH2
expression. In RCC patients with metastatic disease, the
concordance probability including EZH2 expression was
68.4%, compared to 63.0% excluding EZH2 expression.
These values are in a similar range as obtained by the
University of California Los Angeles Integrated Staging
System (UISS) [32], a well-accepted prognostic factor
model for RCC with good predictive accuracy, which
exhibits a concordance index of 76% [32]. Including
molecular markers to the clinical models increased the
concordance probability, in our model as well as in the
UISS model [33,34]. Therefore, EZH2 should represent
a powerful new marker for predicting prognosis in RCC
and could be integrated in established prognostic mod-
els to provide an even better consultation for patients
regarding diagnosis, treatment, and follow-up.
Our findings concerning the prognostic value of EZH2
in RCC, are in contrast to a recent study of 119 clear
cell carcinoma patients, who reported that high tumor
EZH2 levels indicate less aggressive tumor phenotypes
with a favorable prognosis, as assessed by real-time RT-
PCR [35]. We do not know whether this discrepancy is
related to the different detection method for EZH2
expression. Our results are in line with studies in several
other tumor forms, including malignant melanoma and
cancers of the breast, prostate, endometrium, stomach,
and liver, where increased EZH2 expression has been
linked to more aggressive tumor behaviour and poor
prognosis [7,9,17,36,37]. EZH2 expression showed signif-
icant prognostic impact in melanoma, prostate, and
endometrial carcinoma in univariate survival analyses,
but revealed independent multivariate prognostic impor-
tance only in carcinoma of the endometrium and pros-
tate [17]. In breast cancer, high EZH2 expression was a
strong independent predictive parameter of outcome,
providing a better information about CSS than other
independent prognostic features [7]. Thus, EZH2 may
be an interesting novel prognostic marker for a large
panel of different cancer types.
RCCs exhibited significantly higher EZH2 expression
levels than histologically normal kidney, indicating that an
increase in EZH2 expression is acquired during RCC
tumorigenesis. Increased EZH2 expression in tumorous
versus corresponding normal tissue has been also reported
for other cancers as well, including malignant melanoma,
prostate carcinoma, breast cancer and hepatocellular carci-
noma [7,9,17,37]. However, it should be noted that infil-
trating lymphocytes and, sporadically, proximal and distal
tubule epithelial cells stained positive for EZH2 in normal
renal tissue. This indicates that detectable EZH2 expres-
sion is not stringently restricted to tumor cells. In line,
EZH2 expression could be detected in the proliferating
Table 4 Analysis of cancer specific survival (CSS) in RCC, patients with metastases
Univariate Analysis Multivariate Analysis
Variable HR 95% CI p HR 95% CI p
Grading 2 vs. 1 0.59 0.24-1.44 0.247 0.65 0.25-1.74 0.395
Grading 3/4 vs. 1 1.03 0.43-2.45 0.950 1.18 0.47-3.01 0.725
Karnofsky < 80 vs. ≥ 80 1.90 0.99-3.64 0.054 2.24 0.99-5.05 0.052
Age ≥ 65 years vs. < 65 years 1.39 0.84-2.31 0.202 1.47 0.79-2.73 0.228
Sex (Male vs. Female) 1.28 0.75-2.19 0.372 1.35 0.74-2.45 0.331
Clear cell RCC vs. non clear cell RCC 0.59 0.25-1.38 0.223 0.36 0.15-0.88 0.025
Nuclear EZH2 1-5% vs. 0% 2.18 0.95-5.00 0.065 2.63 1.03-6.71 0.043
Nuclear EZH2 >5-25% vs. 0% 2.92 1.22-6.97 0.016 3.35 1.29-8.74 0.013
Nuclear EZH2 >25-50% vs. 0% 3.91 1.51-10.16 0.005 4.92 1.72-14.10 0.003
Nuclear EZH2 >50% vs. 0% 0.98 0.25-3.91 0.978 0.70 0.13-3.75 0.677
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Page 8 of 10parabasal cell layer in normal cervical epithelium [14] and
in proliferating cells of normal mammary gland tissue
[38]. Interestingly, the latter study raised the possibility
that EZH2 is expressed in mammary stem cells, in line
with studies indicating a dual role of the PcG proteins in
self-renewal of stem cells and oncogenesis [39,40].
Apart form serving as a novel prognostic marker in
RCC, EZH2 expression may also have therapeutic and
diagnostic implications. Mechanistically, EZH2 is likely
to contribute to the growth of RCC cells, since silencing
of EZH2 expression exerts profound anti-proliferative
effects in RCC lines [13]. These findings indicate that
EZH2 may represent a novel therapeutic target for RCC
treatment in that specific EZH2 inhibitors should repress
tumor growth. Under diagnostic aspects, it is noteworthy
that upregulation of EZH2 expression can be detected
very early in breast cancer development, even before aty-
pic cells are histologically evident [15,16]. Thus, the
determination of EZH2 expression may be an important
new tool to identify patients at risk for developing breast
cancer [15,16]. In view of the substantial portion of RCCs
expressing EZH2, it will be interesting to investigate in
future studies whether EZH2 expression is an early event
in RCC development and may also have diagnostic
potential for RCC detection.
Conclusions
We here identified EZH2 expression as a novel, powerful,
and independent unfavourable prognostic marker for
CSS in patients with both metastatic and non-metastatic
RCC. Assessment of the EZH2 status could therefore be
integrated in established prognostic models in order to
improve clinical management of RCC patients. The high
proportion of RCCs showing increased EZH2 protein
levels may also have therapeutic implications, since tar-
geted inhibition of EZH2 expression has been shown to
repress tumor cell growth.
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